研究室業績2007-2020

20202019201820172016201520142013201220112010200920082007

2013

上皮間葉転換シグナル ―治療の標的としての可能性―

有馬好美
QIAGEN eyes 2013 Issue 7

【活性酸素-基礎から病態解明・制御まで】疾患病態・臨床編 癌幹細胞における酸化ストレス回避機構

永野 修, 佐谷 秀行
医学のあゆみ 2013 Nov 247巻9号 Page983-988

がん幹細胞に対する標的治療の展開

設楽 紘平, 土井 俊彦, 大津 敦, 永野 修, 佐谷 秀行
腫瘍内科 2013 Nov 12巻5号 Page569-576

Lysyl oxidase is induced by cell density-mediated cell cycle suppression via RB-E2F1-HIF-1α axis.

Goto TM, Arima Y, Nagano O, Saya H
Cell Struct Funct. 2013 Nov;38(1):9-14.

Identification of novel small compounds that restore E-cadherin expression and inhibit tumor cell motility and invasiveness.

Hirano T, Satow R, Kato A, Tamura M, Murayama Y, Saya H, Kojima H, Nagano T, Okabe T, Fukami K.
Biochem Pharmacol. 2013 Nov 15;86(10):1419-29. doi: 10.1016/j.bcp.2013.09.001.

Katanin p60 contributes to microtubule instability around the midbody and facilitates cytokinesis in rat cells.

Matsuo M, Shimodaira T, Kasama T, Hata Y, Echigo A, Okabe M, Arai K, Makino Y, Niwa S, Saya H, Kishimoto T.
PLoS One. 2013 Nov 26;8(11):e80392. doi: 10.1371/journal.pone.0080392.

In vivo pH monitoring using boron doped diamond microelectrode and silver needles: application to stomach disorder diagnosis.

Fierro S, Seishima R, Nagano O, Saya H, Einaga Y.
Sci Rep. 2013 Nov 19;3:3257. doi: 10.1038/srep03257.

Redox regulation in stem-like cancer cells by CD44 variant isoforms.

Nagano O, Okazaki S, Saya H.
Oncogene. 2013 Oct 31;32(44):5191-8. doi: 10.1038/onc.2012.638.

Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia.

Wada T, Ishimoto T, Seishima R, Tsuchihashi K, Yoshikawa M, Oshima H, Oshima M, Masuko T, Wright NA, Furuhashi S, Hirashima K, Baba H, Kitagawa Y, Saya H, Nagano O.
Cancer Sci. 2013 Oct;104(10):1323-9. doi: 10.1111/cas.12236.

Characteristics of glioma stem cells.

Sampetrean O, Saya H.
Brain Tumor Pathol. 2013 Oct;30(4):209-14. doi: 10.1007/s10014-013-0141-5.

Energy management by enhanced glycolysis in G1-phase in human colon cancer cells in vitro and in vivo.

Bao Y, Mukai K, Hishiki T, Kubo A, Ohmura M, Sugiura Y, Matsuura T, Nagahata Y, Hayakawa N, Yamamoto T, Fukuda R, Saya H, Suematsu M, Minamishima YA.
Mol Cancer Res. 2013 Sep;11(9):973-85. doi: 10.1158/1541-7786.MCR-12-0669-T.

Three-dimensional culture of sebaceous gland cells revealing the role of prostaglandin E2-induced activation of canonical Wnt signaling.

Yoshida GJ, Saya H, Zouboulis CC.
Biochem Biophys Res Commun. 2013 Sep 6;438(4):640-6. doi: 10.1016/j.bbrc.2013.07.129.

Statins decrease lung inflammation in mice by upregulating tetraspanin CD9 in macrophages.

Jin Y, Tachibana I, Takeda Y, He P, Kang S, Suzuki M, Kuhara H, Tetsumoto S, Tsujino K, Minami T, Iwasaki T, Nakanishi K, Kohmo S, Hirata H, Takahashi R, Inoue K, Nagatomo I, Kida H, Kijima T, Ito M, Saya H, Kumanogoh A.
PLoS One. 2013 Sep 9;8(9):e73706. doi: 10.1371/journal.pone.0073706.

【がん幹細胞の基礎と臨床】固形腫瘍における癌幹細胞の生物学

吉田 剛, 佐谷 秀行
Medical Science Digest 2013 Aug 39巻9号 Page412-415

Acquired expression of NFATc1 downregulates E-cadherin and promotes cancer cell invasion.

Oikawa T, Nakamura A, Onishi N, Yamada T, Matsuo K, Saya H.
Cancer Res. 2013 Aug 15;73(16):5100-9. doi: 10.1158/0008-5472.CAN-13-0274.

Twist2 functions as a tumor suppressor in murine osteosarcoma cells.

Ishikawa T, Shimizu T, Ueki A, Yamaguchi SI, Onishi N, Sugihara E, Kuninaka S, Miyamoto T, Morioka H, Nakayama R, Kobayashi E, Toyama Y, Mabuchi Y, Matsuzaki Y, Yamaguchi R, Miyano S, Saya H.
Cancer Sci. 2013 Jul;104(7):880-8. doi: 10.1111/cas.12163.

CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence.

Hirata K, Suzuki H, Imaeda H, Matsuzaki J, Tsugawa H, Nagano O, Asakura K, Saya H, Hibi T.
Br J Cancer. 2013 Jul 23;109(2):379-86. doi: 10.1038/bjc.2013.314.

Targeting Aurora B to the equatorial cortex by MKlp2 is required for cytokinesis.

Kitagawa M, Fung SY, Onishi N, Saya H, Lee SH.
PLoS One. 2013 Jun 4;8(6):e64826. doi: 10.1371/journal.pone.0064826.

大腸癌の分子生物学 消化器癌におけるCD44の機能的役割

吉田 剛, 佐谷 秀行
大腸癌Frontier 2013 Jun 6巻1号 Page53-58

がん幹細胞の概念に基づく治療戦略のパラダイムシフト

佐谷 秀行
尿路悪性腫瘍研究会記録39巻 2013 Apr Page55-67

The Arf/p53 protein module, which induces apoptosis, down-regulates histone H2AX to allow normal cells to survive in the presence of anti-cancer drugs.

Atsumi Y, Inase A, Osawa T, Sugihara E, Sakasai R, Fujimori H, Teraoka H, Saya H, Kanno M, Tashiro F, Nakagama H, Masutani M, Yoshioka K.
J Biol Chem. 2013 May 10;288(19):13269-77. doi: 10.1074/jbc.M112.402560.

cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes.

Kim M, Kim M, Lee S, Kuninaka S, Saya H, Lee H, Lee S, Lim DS.
EMBO J. 2013 May 29;32(11):1543-55. doi: 10.1038/emboj.2013.102.

APC(CDH1) targets MgcRacGAP for destruction in the late M phase.

Nishimura K, Oki T, Kitaura J, Kuninaka S, Saya H, Sakaue-Sawano A, Miyawaki A, Kitamura T.
PLoS One. 2013 May 16;8(5):e63001. doi: 10.1371/journal.pone.0063001. Print 2013.

IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells.

Osuka S, Sampetrean O, Shimizu T, Saga I, Onishi N, Sugihara E, Okubo J, Fujita S, Takano S, Matsumura A, Saya H.
Stem Cells. 2013 Apr;31(4):627-40. doi: 10.1002/stem.1328.

がんモデルマウス・ラットライブラリ(第8回) 脳腫瘍モデル

大久保 淳, Sampetrean Oltea, 佐谷 秀行
細胞工学 2013 Feb 32巻3号 Page338-343

【胆道癌、膵癌に対する個別化治療の新展開】分子標的薬に対する治療抵抗性のメカニズム

吉田 剛, 佐谷 秀行
胆と膵 2013 Feb 34巻2号 Page131-135

【がんのheterogeneity-その解明と攻略への次なる一手 微小環境、がん幹細胞、ゲノム変異の統合的理解からがんの"不均一性"に挑む】概論 Heterogeneity がん治療最大の障壁に迫る

藤田 恭之, 佐谷 秀行
実験医学 2013 Jan 31巻1号 Page2-7

【がんのheterogeneity-その解明と攻略への次なる一手 微小環境、がん幹細胞、ゲノム変異の統合的理解からがんの"不均一性"に挑む】CD44によって制御されるがん組織の不均一性

永野 修, 佐谷 秀行
実験医学 2013 Jan 31巻1号 Page27-32

m1VacA依存性ROS産生亢進によるoncoprotein CagA分解性autophagy発動機構

津川 仁
日本ヘリコバクター学会誌 2013 Jan 14巻2号 Page15-18

Characteristics of glioma stem cells (Review article).

Sampetrean O and Saya H
Brain Tumor Pathol. 2013 Apr 13. [Epub ahead of print]

Twist2 functions as a tumor suppressor in murine osteosarcoma cells.

Ishikawa T, Shimizu T, Ueki A, Yamaguchi S, Onishi N, Sugihara E, Kuninaka S, Miyamoto T, Morioka H, Nakayama R, Kobayashi E, Toyama Y, Mabuchi Y, Matsuzaki Y, Yamaguchi R, Miyano S and Saya H Cancer Sci. 2013 Apr 4. doi: 10.1111/cas.12163. [Epub ahead of print]

Establishment of HRAS(G12V) transgenic medaka as a stable tumor model for in vivo screening of anticancer drugs.

Matsuzaki Y, Hosokai H, Mizuguchi Y, Fukamachi S, Shimizu A, Saya H.
PLoS One. 2013;8(1):e54424. doi: 10.1371/journal.pone.0054424. Epub 2013 Jan 14.

IGF1 Receptor Signaling Regulates Adaptive Radioprotection in Glioma Stem Cells.

Osuka S, Sampetrean O, Shimizu T, Saga I, Onishi N, Sugihara E, Okubo J, Fujita S, Takano S, Matsumura A, Saya H.
Stem Cells. 2012 Apr;31(4):627-40. doi: 10.1002/stem.1328.

Redox regulation in stem-like cancer cells by CD44 variant isoforms (Review article).

Nagano O, Okazaki S and Saya H
Oncogene. 2013 Jan 21. doi: 10.1038/onc.2012.638. [Epub ahead of print]

xCT Inhibition Depletes CD44v-Expressing Tumor Cells That Are Resistant to EGFR-Targeted Therapy in Head and Neck Squamous Cell Carcinoma.

Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K, Kawashiri S, Mukai M, Asoda S, Kawana H, Nakagawa T, Saya H, Nagano O.
Cancer Res. 2013 Mar 15;73(6):1855-66. doi: 10.1158/0008-5472.CAN-12-3609-T. Epub 2013 Jan 14.

Lysyl oxidase is induced by cell density-mediated cell cycle suppression via RB-E2F1-HIF-1α axis.

Goto TM, Arima Y, Nagano O, Saya H.
Cell Struct Funct. 2013 Jan 19;38(1):9-14. Epub 2012 Nov 30.

Complexity of cancer stem cells (Review Article).

Sugihara E, Saya H.
Int J Cancer. 2013 Mar 15;132(6):1249-59. doi: 10.1002/ijc.27961. Epub 2012 Dec 17. Review.

The APC/C activator Cdh1 regulates the G2/M transition during differentiation of placental trophoblast stem cells.

Naoe H, Chiyoda T, Ishizawa J, Masuda K, Saya H, Kuninaka S.
Biochem Biophys Res Commun. 2013 Jan 11;430(2):757-62. doi: 10.1016/j.bbrc.2012.11.075. Epub 2012 Dec 1.

共同研究2007-2013

2013

APC(CDH1) Targets MgcRacGAP for Destruction in the Late M Phase.

Nishimura K, Oki T, Kitaura J, Kuninaka S, Saya H, Sakaue-Sawano A, Miyawaki A, Kitamura T.
PLoS One. 2013 May 16;8(5):e63001. doi: 10.1371/journal.pone.0063001. Print 2013.

cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes.

Kim M, Kim M, Lee S, Kuninaka S, Saya H, Lee H, Lee S, Lim DS.
EMBO J. 2013 May 3. doi: 10.1038/emboj.2013.102. [Epub ahead of print]

The Arf/p53 Protein Module, Which Induces Apoptosis, Down-regulates Histone H2AX to Allow Normal Cells to Survive in the Presence of Anti-cancer Drugs.

Atsumi Y, Inase A, Osawa T, Sugihara E, Sakasai R, Fujimori H, Teraoka H, Saya H, Kanno M, Tashiro F, Nakagama H, Masutani M, Yoshioka K.
J Biol Chem. 2013 May 10;288(19):13269-77. doi: 10.1074/jbc.M112.402560. Epub 2013 Mar 27.

Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells.

Kai K, Iwamoto T, Kobayashi T, Arima Y, Takamoto Y, Ohnishi N, Bartholomeusz C, Horii R, Akiyama F, Hortobagyi GN, Pusztai L, Saya H and Ueno NT
Oncogene. 2013 Feb 4. doi: 10.1038/onc.2012.609. [Epub ahead of print]

Arf and p53 act as guardians of a quiescent cellular state by protecting against immortalization of cells with stable genomes.

Osawa T, Atsumi Y, Sugihara E, Saya H, Kanno M, Tashiro F, Masutani M, Yoshioka K.
Biochem Biophys Res Commun. 2013 Mar 1;432(1):34-9. doi: 10.1016/j.bbrc.2013.01.091. Epub 2013 Jan 31.

Gene expression profile of a newly established choriocarcinoma cell line, iC3-1, compared to existing choriocarcinoma cell lines and normal placenta.

Kobayashi Y, Banno K, Shimizu T, Ueki A, Tsuji K, Masuda K, Kisu I, Nomura H, Tominaga E, Nagano O, Saya H, Aoki D.
Placenta. 2013 Feb;34(2):110-8. doi: 10.1016/j.placenta.2012.11.003. Epub 2012 Nov 28.